Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Male or female ≥18 years of age
• Prior diagnosis of MM as defined according to IMWG criteria and relapsed or refractory to the last line of therapy
• Eastern Co-operative Oncology Group (ECOG) performance status of 0 to 2
• Adequate hematological, renal and hepatic function
• Willingness to use highly effective contraceptive measures (if sexually active) with all sexual partners

You cannot join if

• Use of any investigational agent, chemotherapy, immunotherapy or anticancer agent from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment, whichever is shortest
• Prior treatment with p300/CBP bromodomain inhibitors
• Known or suspected severe allergies to any active or inactive ingredients in the study medications (inobrodib, pomalidomide, dexamethasone) or any prior immunomodulatory drug (lenalidomide, thalidomide)
• Treatment with medicines or herbal supplements or foods (e.g. strong CYP3A4 inducers or inhibitors) that would interfere with treatment
• Major surgery within 4 weeks of the first dose of study treatment
• Live vaccine within 4 weeks of study treatment
• Active or unresolved adverse events
• Active malignancies (progressing or requiring change in treatment) in the last 24 months other than multiple myeloma
• Female patients who are pregnant or breast-feeding at any time during the study
• Any illness or medical history that would impact safety or compliance with study requirements or impact ability to interpret study data

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

p300/CBP bromodomain inhibitor CCS1477. An orally bioavailable, small molecule inhibitor of the highly conserved bromodomains of the histone acetyltransferase (HAT) paralogs, p300 (E1A-associated protein p300; p300 HAT) and CREB binding protein (CBP), with potential antineoplastic activity. Upon oral administration, p300/CBP bromodomain inhibitor CCS1477 selectively and reversibly binds to the bromodomains of p300 and CBP. This disrupts the acetylation of histones and other proteins and prevents the co-activation of key transcription factors that contribute to tumor progression including the androgen receptor (AR), androgen receptor splice variants (AR-SV), hypoxia-inducible factor 1-alpha (HIF-1-alpha) and Myc proto-oncogene protein (c-Myc). The HAT paralogs p300 and CBP are key transcriptional co-activators that are essential for a multitude of cellular processes and are implicated in the progression and therapeutic resistance of certain cancers. NCI Drug Dictionary

Treatments listed in the registry

• Inobrodib (Drug): 20 mg orally twice daily (b.i.d.) 4 days on / 3 days off for each 28-day cycle.
• Pomalidomide (Drug): 4 mg orally once daily on Day 1 to 21 of each 28-day cycle
• Dexamethasone (Drug): 40 mg orally once daily on Days 1, 8, 15 and 22 for each 28-day cycle

Na · Single Group · masking: None

Main goals

• Objective Response Rate, defined as the percentage of patients with a confirmed partial response (PR) or better, based on IMWG criteria and assessed by Independent Review Committee (IRC) (Assessed from enrollment to date of progressive disease or death from any cause, until the end of study (up to 48 months))

Other goals

• ORR, defined as the percentage of patients with a confirmed PR or better, based on IMWG criteria assessed by Investigator
• Duration of Response (DoR), defined as the duration of overall response by investigator and IRC
• Time to Response (TTR), defined as time to confirmed PR or better, by investigator and IRC
• Very Good Partial Response (VGPR) or better rate, defined as the percentage of patients with a confirmed VGPR or better, based on IMWG criteria and assessed by investigator and IRC
• Complete Response (CR) or better rate, defined as the percentage of patients with a confirmed CR or better, based on IMWG criteria and assessed by investigator and IRC
• Progression Free Survival (PFS), defined as the time from enrolment until the earliest date of Progressive Disease (PD), or death due to any cause, and assessed by investigator and IRC
• Overall Survival (OS), defined as the time from enrolment to the date of death due to any cause
• Incidence of treatment-emergent adverse events (TEAEs), vital signs and laboratory abnormalities

Planned enrollment: 100 (estimated).

• Mayo Clinic Arizona, Phoenix, Arizona
• University of California, San Francisco, San Francisco, California
• Mayo Clinic Florida, Jacksonville, Florida
• H Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
• Winship Cancer Institute, Atlanta, Georgia
• University of Chicago Medical Center, Chicago, Illinois
• University of Iowa Health Care, Iowa City, Iowa
• American Oncology Partners, PA, Bethesda, Maryland
• Dana-Farber Cancer Institute, Boston, Massachusetts
• University of Michigan, Ann Arbor, Michigan
• Mayo Clinic, Rochester, Minnesota
• Washington University School of Medicine, St Louis, Missouri
• University of Nebraska Medical Center, Omaha, Nebraska
• John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey
• Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
• Levine Cancer Institute, Charlotte, North Carolina
• Wake Forest University Health Sciences, Winston-Salem, North Carolina
• Cleveland Clinic, Cleveland, Ohio
• University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania
• Fred Hutchinson Cancer Center, Seattle, Washington
• Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

10 recruiting sites outside the US. Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT07096778
• NCI Drug Dictionary: C160195

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Sep 20, 2026. Public record; not medical advice.